Edgestream Partners L.P. Has $3.62 Million Stock Holdings in Bruker Corporation (NASDAQ:BRKR)

Edgestream Partners L.P. lowered its holdings in Bruker Corporation (NASDAQ:BRKR - Free Report) by 22.3% in the first quarter, according to its most recent disclosure with the SEC. The institutional investor owned 86,826 shares of the medical research company's stock after selling 24,979 shares during the period. Edgestream Partners L.P. owned approximately 0.06% of Bruker worth $3,624,000 at the end of the most recent reporting period.

Other hedge funds also recently added to or reduced their stakes in the company. Pinnacle Bancorp Inc. purchased a new stake in shares of Bruker during the first quarter worth approximately $29,000. Allworth Financial LP increased its position in shares of Bruker by 92.4% in the 1st quarter. Allworth Financial LP now owns 758 shares of the medical research company's stock valued at $30,000 after purchasing an additional 364 shares during the last quarter. MassMutual Private Wealth & Trust FSB raised its holdings in shares of Bruker by 274.9% in the 1st quarter. MassMutual Private Wealth & Trust FSB now owns 1,091 shares of the medical research company's stock valued at $46,000 after purchasing an additional 800 shares in the last quarter. Fifth Third Bancorp lifted its position in shares of Bruker by 54.2% during the 1st quarter. Fifth Third Bancorp now owns 1,109 shares of the medical research company's stock worth $46,000 after purchasing an additional 390 shares during the last quarter. Finally, Quadrant Capital Group LLC increased its holdings in Bruker by 18.2% in the fourth quarter. Quadrant Capital Group LLC now owns 1,273 shares of the medical research company's stock valued at $75,000 after buying an additional 196 shares during the last quarter. 79.52% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of research analysts recently commented on the stock. UBS Group dropped their target price on shares of Bruker from $57.00 to $45.00 and set a "neutral" rating on the stock in a research report on Thursday, May 8th. The Goldman Sachs Group lowered their target price on shares of Bruker from $50.00 to $45.00 and set a "neutral" rating on the stock in a research report on Thursday, May 8th. Stifel Nicolaus reduced their price target on shares of Bruker from $57.00 to $48.00 and set a "hold" rating for the company in a research report on Thursday, May 8th. Barclays lowered their price target on Bruker from $50.00 to $46.00 and set an "overweight" rating on the stock in a report on Thursday, May 8th. Finally, Bank of America lowered their target price on Bruker from $61.00 to $50.00 and set a "buy" rating on the stock in a research note on Thursday, June 26th. Six research analysts have rated the stock with a hold rating and four have given a buy rating to the company's stock. Based on data from MarketBeat, Bruker currently has a consensus rating of "Hold" and a consensus price target of $52.89.

Bruker Trading Down 3.9%

Shares of BRKR traded down $1.64 on Friday, hitting $40.55. 2,181,482 shares of the stock traded hands, compared to its average volume of 1,788,987. The firm has a market capitalization of $6.14 billion, a P/E ratio of 77.98, a P/E/G ratio of 2.73 and a beta of 1.18. The company has a quick ratio of 0.74, a current ratio of 1.57 and a debt-to-equity ratio of 1.13. Bruker Corporation has a 1 year low of $34.10 and a 1 year high of $72.94. The stock's 50 day moving average is $39.43 and its two-hundred day moving average is $44.89.

Bruker (NASDAQ:BRKR - Get Free Report) last issued its quarterly earnings data on Wednesday, May 7th. The medical research company reported $0.47 EPS for the quarter, topping analysts' consensus estimates of $0.46 by $0.01. The company had revenue of $801.40 million for the quarter, compared to analysts' expectations of $763.83 million. Bruker had a return on equity of 19.47% and a net margin of 2.31%. The firm's quarterly revenue was up 11.0% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.53 earnings per share. As a group, sell-side analysts predict that Bruker Corporation will post 2.69 earnings per share for the current year.

Bruker Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Friday, June 27th. Stockholders of record on Monday, June 16th were issued a $0.05 dividend. The ex-dividend date of this dividend was Monday, June 16th. This represents a $0.20 annualized dividend and a dividend yield of 0.49%. Bruker's dividend payout ratio (DPR) is 38.46%.

Insiders Place Their Bets

In related news, CEO Frank H. Laukien acquired 2,608 shares of Bruker stock in a transaction dated Friday, June 6th. The stock was acquired at an average cost of $38.36 per share, with a total value of $100,042.88. Following the purchase, the chief executive officer directly owned 38,462,171 shares in the company, valued at $1,475,408,879.56. The trade was a 0.01% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 27.30% of the company's stock.

About Bruker

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.